Kaplan–Meier analysis evaluated the survival rate of patients with liver cancer, lung adenocarcinoma, and breast cancer, and found that patients with high GPR162 expression had a better prognosis (Fig. 5c–e). This evidence concerns the gene GPR162 and lung adenocarcinoma.